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Abstract
Introduction:  Salivary  gland  tumors  (SGTs)  are  rare  head  and  neck  malignancies  consisting  of  a
spectrum  of  tumors  with  different  biological  behaviors.
Objective:  In  this  study  we  aimed  to  ﬁnd  out  differential  expression  of  microRNA  proﬁles
between  benign  and  malignant  SGTs.
Methods:  We  investigated  the  possible  role  of  95  microRNAs  in  the  20  patients  with  salivary
gland tumors  with  comparison  of  17  patients  without  malignancy  or  salivary  gland  diseases.
Sixteen of  the  tumors  were  benign  (seven  pleomorphic  adenomas,  nine  Warthin  tumors),  four
of them  were  malignant  (two  squamous  cell  carcinomas,  one  high  grade  mucoepidermoid  carci-
noma, one  adenocarcinoma).  Serum  and  saliva  samples  were  collected  from  both  patients  and
control group.  Tissue  samples  of  tumor  masses  were  also  collected  from  patient  group.
Results: Among  studied  microRNAs  miR-21,  miR-23a,  miR-27a,  miR-223,  miR-125b,  miR-126,
miR-146a,  miR-30e  were  down  regulated  in  the  benign  group  compared  to  control  group  in  the
serum samples  (p-values  are  0.04,  0.00005,  0.00005,  0.0022,  0.031,  0.00008,  0.044,  and  0.0007,
respectively).  When  tissue  samples  were  studied  miR-21,  miR-31,  miR-199a-5p,  miR-146b,  miR-
345 were  up-regulated  in  the  malignant  group  compared  to  benign  group  (p  values  are  0.006,
0.02, 0.013,  0.013,  0.041,  respectively).  miR-30e  showed  statistically  signiﬁcant  up-regulation
in malignant  tumor  group’s  plasma  samples  compared  to  benign  group  (p  =  0.034).  There  was
no statistically  signiﬁcant  difference  in  saliva  samples  between  groups.
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Conclusion:  Our  results  showed  that  different  microRNAs  may  play  role  in  salivary  tumor  patho-
genesis according  to  biological  behavior.  Although  there  was  no  difference  in  saliva  samples
between  groups,  according  to  tissue  and  serum  samples  miR-21  and  30e  may  have  an  important
role; since  they  were  down-regulated  in  benign  tumors  whereas  up-regulated  in  malignant  ones.
© 2016  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
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Comparac¸ão  de  perﬁs  de  microRNA  entre  tumores  de  glândula  salivar  benignos  e
malignos  em  amostras  de  tecido,  sangue  e  saliva:  estudo  prospectivo  de  controle  de
caso
Resumo
Introduc¸ão:  Os  tumores  da  glândula  salivar  (TGS)  são  lesões  malignas  raras  de  cabec¸a  e  pescoc¸o
que consistem  em  um  espectro  de  tumores  com  diferentes  comportamentos  biológicos.
Objetivo:  Neste  estudo,  tivemos  como  objetivo  identiﬁcar  a  expressão  diferencial  de  perﬁs  de
microRNA entre  TGS  benignos  e  malignos.
Método:  Investigamos  a  possível  participac¸ão  de  95  microRNA  em  20  pacientes  com  tumores
de glândulas  salivares  comparado  a  17  pacientes  sem  doenc¸a  maligna  ou  doenc¸as  das  glândulas
salivares. Dezesseis  dos  tumores  eram  benignos  (sete  adenomas  pleomórﬁcos,  nove  tumores  de
Warthin),  quatro  deles  eram  malignos  (dois  carcinomas  espinocelulares,  carcinoma  mucoepi-
dermoide de  alto  grau,  um  adenocarcinoma).  As  amostras  de  soro  e  saliva  foram  coletadas
de pacientes  e  do  grupo  controle.  Amostras  de  tecido  dos  tumores  também  foram  colhidas  do
grupo de  pacientes.
Resultados:  Entre  os  microRNA  estudados,  miR-21,  miR-23a,  miR-27a,  miR-223,  miR-125b,  miR-
126, miR-146a,  miR-30e  foram  infrarregulados  no  grupo  benigno  em  comparac¸ão  ao  grupo
controle  nas  amostras  do  soro  (os  valores  de  p  são  0,04,  0,00005,  0,00005,  0,0022,  0,031,
0,00008, 0,044  e  0,0007,  respectivamente).  Quando  as  amostras  de  tecido  foram  estudadas,
miR-21, o  miR-31,  o  miR-199-5p,  miR-146b,  o  miR-345  foram  suprarregulados  no  grupo  maligno
em relac¸ão  ao  grupo  benigno  (valores  de  p  são  0,006,  0,02,  0,013,  0,013,  0,041,  respectiva-
mente). O  miR-30e  apresentou  suprarregulac¸ão  estatisticamente  signiﬁcativa  em  amostras  de
plasma do  grupo  de  tumor  maligno  em  relac¸ão  ao  grupo  benigno  (p  =  0,034).  Não  houve  diferenc¸a
estatisticamente  signiﬁcativa  em  amostras  de  saliva  entre  os  grupos.
Conclusão:  Nossos  resultados  mostraram  que  diferentes  microRNA  podem  desempenhar  um
papel na  patogenia  do  tumor  salivar  de  acordo  com  o  comportamento  biológico.  Embora  não
tenha havido  diferenc¸a  em  amostras  de  saliva  entre  os  grupos,  de  acordo  com  as  amostras  de
tecido e  de  soro,  miR-21  e  30e  podem  ter  um  papel  importante,  já  que  foram  infrarregulados
nos tumores  benignos  enquanto  suprarregulados  nos  tumores  malignos.
© 2016  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este  é  um  artigo  Open  Access  sob  a  licença  de  CC  BY
(http://creativecommons.org/licenses/by/4.0/).
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alivary  gland  tumors  (SGT)  comprise  only  3--5%  of  all  head
nd  neck  malignancies;  they  have  at  least  24  different  types
ccording  to  World  Health  Organization  2005  classiﬁcation.1
mong  these  pleomorphic  adenoma  is  the  most  common
enign  tumor  whereas  mucoepidermoid  carcinoma  is  the
ost  common  malignant  one.2 The  exact  pathogenesis  and
ay  to  malignant  transformation  for  salivary  gland  tumors
re  not  well  known.  Although  cigarette  smoking  and  alco-
ol  consumption  are  important  risk  factors  for  head  and
quamous  Cell  Carcinomas  (SCC),  they  are  not  admissible
or  salivary  gland  tumors,  and  occupational  exposures  are
nlikely  to  take  part  in  the  pathogenesis.3
f
t
i
kMicroRNAs  (miRNAs)  are  a  group  of  endogenous  21--25
ucleotide  noncoding  RNAs  which  target  gene  coding
n  the  posttranscriptional  level.4,5 They  are  involved  in
arious  important  biological  processes  such  as  develop-
ent,  differentiation,  proliferation  and  apoptosis.5 They
an  behave  like  oncogenes  or  tumor  suppressor  genes;
heir  up  regulation  or  down  regulation  may  take  part  in
arcinogenesis.6 Among  head  and  neck  cancers  SCC  and
mong  salivary  gland  malignancies  Adenoid  Cystic  Car-
inomas  (ACCs)  are  the  most  common  cancers  studied
4--7or  possible  role  of  miRNAs  in  cancer  pathogenesis. In
his  study  we  investigated  the  possible  role  of  miRNAs
n  salivary  gland  tumor  pathogenesis.  To  the  best  of  our
nowledge;  this  is  the  ﬁrst  study  with  comparing  serum,
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When  benign  tumors  were  compared  with  control  group;
8  miRNAs  (miR-21,  miR-23a,  miR-27a,  miR-223,  miR-125b,
miR-126,  miR-146a,  and  miR-30e)  as  shown  in  Fig.  1,  had  sta-
tistically  signiﬁcant  down-regulation  in  benign  tumor  group
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MicroRNA  proﬁles  of  benign  and  malignant  salivary  gland  tum
saliva  and  tissue  levels  of  miRNAs  among  salivary  gland  neo-
plasms.
Methods
Local  ethical  committee  approval  was  acquired  for  our
study.  20  patients  with  salivary  gland  tumors  and  17  sex
and  age  matched  healthy  controls  without  any  salivary  gland
or  systemic  disorders  were  included.  Mean  age  for  sali-
vary  gland  tumor  was  53.1  and  mean  age  for  control  group
was  46.4.  There  were  10  male  (50%)  and  10  female  (50%)
patients  in  tumor  group  and  9  male  (52.9%)  and  8  female
(47.1%)  patients  in  the  control  group.  There  was  no  statis-
tically  signiﬁcant  difference  regarding  age  (p  =  0.251)  and
sex  (p  =  0.858)  between  tumor  and  control  groups.  From  the
tumor  group  there  were  16  benign  and  4  malignant  tumors.
Malignant  ones  were  two  SCCs,  one  high  grade  mucoepi-
dermoid  carcinoma,  one  adenocarcinoma.  Only  the  primary
squamous  cell  carcinomas  were  taken  to  the  study  according
to  Gaughan’s  inclusion  criteria,8,9 metastatic  squamous  cell
carcinomas  were  excluded.  Benign  ones  were  nine  Warthin
tumors  and  seven  pleomorphic  adenomas.  List  of  the  tumors
were  summarized  in  Table  1.  In  the  tumor  group  one  (25%)
of  four  in  the  malignant  group  and  ﬁve  (31.25%)  of  16  in
the  benign  group  were  female.  Regarding  sex  and  age  dif-
ferences  between  malignant  and  benign  tumor  groups,  there
was  no  statistically  different  for  both  sex  (p  =  0.807)  and  age
(p  =  0.9355).
MicroRNA  analysis
Serum  collection
Blood  samples  of  5  mL  were  collected  to  7.5%  EDTA  con-
taining  tubes  from  patient  group  preoperatively  and  control
group.  After  centrifugation  serums  were  collected  and
stored  at  −80 ◦C.
Saliva  collection
After  catheterization  of  the  involved  salivary  gland  ductus,
by  using  lemon  as  sialogogue  200  L saliva  of  the  involved
gland  was  collected.  The  saliva  was  mixed  with  200  L
RNAlater  (QIAGEN  Inc.,  Valencia,  CA)  solution.  After  two
hours  in  room  temperature,  they  were  stored  at  −80 ◦C  in
deep  freezer.10 200  L  saliva  was  also  collected  from  the
control  group.Tissue  collection
Tissue  samples  were  taken  only  from  the  salivary  gland
tumor  group.  During  surgery  for  salivary  gland  tumor;  a
Table  1  Histopathologic  types  of  tumors  in  the  patient
group.
Tumor  type  Percentage
Warthin’s  tumor  9/20  (45%)
Pleomorphic  adenoma  7/20  (35%)
Squamous  cell  carcinoma  2/20  (10%)
High  grade  mucoepidermoid  carcinoma  1/20  (5%)
Adenocarcinoma  1/20  (5%) F
b PRESS
 3
--4  mm3 tumoral  tissue  was  used  for  analysis.  Tissue  sam-
les  were  put  into  1  mL  RNAlater  (QIAGEN  Inc.,  Valencia,
A)  solution.  After  two  hours  in  room  temperature,  they
ere  stored  at  −80 ◦C  in  deep  freezer.  Tissues  were  diced
ith  a  surgical  blade  and  homogenized  with  pestle  and  mor-
ar.  MicroRNA  isolation  from  the  homogenized  tissue  was
one  by  MicroRNA  isolation  kit  (Roche  Diagnostics,  GmbH,
annheim,  Germany)  according  to  manufacturer’s  instruc-
ions.
icroRNA  expression  proﬁling
fter  MicroRNAs  were  isolated  from  serum,  saliva  and  tis-
ue  by  MicroRNA  isolation  kit  (Roche  Diagnostics,  GmbH,
annheim,  Germany)  according  to  manufacturer’s  instruc-
ions;  RNA  samples  converted  to  cDNA  by  using  miScript  II
T  Kit  (Qiagen).  cDNA  samples  are  preampliﬁed  by  using
iScript  Microﬂuidics  PreAMP  Kit  (Qiagen).  qRT-PCR  analy-
is  performed  by  using  miScript  miRNA  Assays  (Qiagen)  with
ynamic  Array  96.96  (Fluidigm)  on  BioMark  System  (Flu-
digm).  Basically  95  types  of  microRNAs  were  studied.
ata  analysis
RT-PCR  results  analyzed  by  using  2−Ct method.11,12
rieﬂy,  up  or  down  regulation  of  microRNAs  were  compared
etween  groups.  Student’s  t-test  was  used  for  analyzing
ge  differences  and  Chi-square  test  was  used  for  analyz-
ng  sex  differences  between  groups.  Expression  data  were
ontrolled  for  normal  distribution  with  the  Shapiro--Wilk
est.  According  to  the  results;  all  data  were  not  nor-
ally  distributed.  Mann--Whitney  U-test  was  used  to  detect
xpression  differences  of  miRNAs  in  serum,  tissue  and  saliva
amples.  p-Value  of  <0.05  was  considered  as  statistically
igniﬁcant.
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igure  1  Comparison  of  plasma  microRNA  expression  proﬁles
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Table  2  MicroRNAs  showing  statistically  signiﬁcant  fold
changes  by  comparing  the  plasma  samples  of  benign  tumor
and control  groups  with  p  values  were  presented.
MicroRNA  type  Fold  regulation  p-Values
Mir-21  −2.5197  0.04
Mir-23a  −13.05  0.00005
Mir-27a  −21.4 0.00005
Mir-125b  −4.644 0.031
Mir-126  −9.2 0.00008
Mir-30e  −64.38  0.0007
Mir-146a  −3.5  0.044
Mir-223  −10.34  0.0022
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ligure  2  Comparison  of  tissue  microRNA  expression  proﬁles
etween  benign  and  malignant  tumor  groups.
n  serum  samples.  Table  2  summarizes  the  fold  regulation
nd  p-values  of  these  miRNAs.  There  was  no  statistically
igniﬁcant  up-regulation  of  miRNAs  in  serum  samples.
When  malignant  tumor  group  patients  were  compared
ith  benign  tumor  group  in  tissue  samples;  5  miRNAs  (miR-
1,  31,  199a,  146b,  345)  showed  statistically  signiﬁcant
p-regulation  in  malignant  tumor  group  (Fig.  2).  Table  3  sum-
arizes  the  fold  regulation  values  in  malignant  tumor  group
ith  p-values.  Heat  map  diagram  of  clustering  of  miRNAs  in
issue  samples  were  shown  in  Fig.  3.  Among  these  miRNAs
iR-199a  also  showed  statistically  signiﬁcant  (p  =  0.042)  up-egulation  in  serum  samples  of  malignant  group  compared
o  benign  group.  miR-30e  showed  15.06  fold  up-regulation
Table  3  MicroRNA  expression  of  malignant  tumor  group
compared  to  benign  tumor  group  in  tissue  samples  showing
statistically  signiﬁcant  fold  changes  were  shown.
MicroRNA  type  Fold  regulation  p-Values
Mir-21  +5.23  0.0006
Mir-31 +2.24  0.02
Mir-199a  +2.36  0.013
Mir-146b  +3.21  0.013
Mir-345  +18.063  0.041
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p  =  0.034)  in  malignant  tumor  group’s  plasma  samples  com-
ared  to  benign  group  (Fig.  4).
When  malignant  tumor  group  was  compared  with  control
roup  miR-23a  showed  10.5  fold  down  regulation  (p  =  0.02)
n  serum  samples  of  malignant  tumors  (data  not  shown).
There  was  no  statistically  signiﬁcant  difference  in  saliva
amples  between  benign,  malignant  and  control  groups.
iscussion
ince  they  were  ﬁrst  found  in  the  nematode  Caenorhabdi-
is  elegans  in  1993,13 miRNAs  have  been  investigated  for
heir  probable  roles  in  normal  physiological  and  diseased
tates  with  several  studies.  They  are  a  class  of  endogenous
mall  RNAs  which  target  gene  expression  in  the  posttrans-
riptional  level  that  negatively  regulate  messenger  RNA
ranslation.4,14 After  transcripted  via  RNA  polymerase  II  or
II,  they  have  multiple  important  biological  behaviors  such
s  proliferation,  differentiation,  apoptosis  and  motility.4,14
hese  important  features  make  them  crucial  in  physiological
evelopment  of  tissues  and  anomalies  in  their  transcription
ay  lead  to  aberrant  differentiation  and  carcinogenesis.6
For  normal  embryological  development  of  salivary
lands,  roles  of  miRNAs  have  been  investigated  by  authors.
n  a  murine  model  Jevnaker  and  Osmundsen15 found  that
here  were  tissue  speciﬁc  miRNAs  in  the  submandibular
land  for  normal  development  such  as  has-miR-28,  150,  222,
99,  322,  329,  341,  375  and  429.  miRNAs  miR-23a,  27a,  223,
25b,  126,  30e  which  were  shown  to  be  down  regulated
n  benign  tumor  group  in  our  study  were  also  expressed  in
ubmandibular  gland  of  mice  embryo.  Also  some  members
f  miRNA  17--92  cluster  such  as  miR-19b,  miR-20a,  miR-
2  were  highly  expressed  during  mice  submandibular  gland
evelopment.14 miR-21  which  was  one  of  the  most  impor-
ant  miRNAs  studied  in  our  report,  is  also  a crucial  miRNA
or  embryological  development  of  submandibular  gland  and
ts  branching  morphogenesis.  It  was  shown  to  be  expressed
n  mesenchymal  tissue  of  mice  submandibular  gland,  this
xpression  was  up-regulated  by  epidermal  growth  factor
hich  has  critical  role  in  branching  of  submandibular  gland
uctus.16
Near  normal  physiological  development  roles  of  miRNAs
n  carcinogenesis  are  also  investigated.  Since  the  ﬁrst  signs
f  their  probable  role  in  carcinogenesis  were  found  by  Calin
t  al. 17 by  down-regulation  of  miR-15a,  miR-16-1  in  chronic
ymphoid  leukemia  in  2002,  several  studies  concerning  rela-
ionship  between  miRNAs  and  carcinogenesis  have  been
ublished.  Among  head  and  neck  cancers  squamous  carci-
oma  is  widely  studied  for  probable  role  of  miRNAs.  Although
here  is  a  wide  difference  between  studies,  miR-21  is  the
nly  constant  miRNA  showing  up  regulation  in  head  and  neck
quamous  cell  cancers.6 It  has  anti-apoptotic,  cell  prolife-
ative  effects  with  promoting  cell  invasion  and  metastases,
o  up  regulation  of  this  miRNA  also  predicts  poor  prognosis
n  head  and  neck  cancers.18 In  our  study  there  was  a  ﬁvefold
p  =  0.0006)  up-regulation  of  miR-21  in  malignant  salivary
land  tumors’  tissue  samples  compared  to  benign  tumors.
here  was  also  a  2.51  fold  down-regulation  (p  =  0.047)  in
lasma  samples  of  benign  group  compared  to  control  group.
his  miRNA  may  have  a  critical  role  in  both  benign  and  sali-
ary  gland  tumor  pathogenesis.
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MicroRNA  proﬁles  of  benign  and  malignant  salivary  gland  tumors  5
Figure  3  Heat  map  diagram  of  patients’  microRNA  expression  proﬁles  in  tissue  samples  was  presented.  P  (patient)  8,  9,  18,  20
were malignant  salivary  gland  tumor  patients,  others  were  benign  ones.
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mon  target  genes  of  these  miRNAs.  (These  genes  wereigure  4  Comparison  of  plasma  samples  of  benign  and  malig-
ant tumor  group  for  microRNA  expression  proﬁles.
In  our  study  miR-125b  was  shown  to  be  down  regulated
n  serum  samples  of  benign  salivary  gland  tumors.  miR-125b
nd  miR-100  are  two  important  miRNAs  mapping  the  chro-
osome  11.  Alterations  in  this  chromosome  may  lead  to
oth  oral  cancers  and  mucoepidermoid  carcinoma  of  salivary
land.19,20 In  the  study  of  Hui  et  al.18 expression  of  miR-125b
as  also  down  regulated  in  head  and  neck  squamous  cell  car-
inoma  like  our  study.  Down  regulation  of  this  miRNA  may
ause  increased  cell  proliferation  and  carcinogenesis.19
MiR-23a  and  miR-27a  belong  to  miR  23a∼27a∼24-2
luster  located  on  chromosome  9q22.  They  have  multi-
le  functions  in  both  healthy  and  disease  states  such
s  cell  cycle,  proliferation,  differentiation  and  cardiac
ypertrophy.21 Literature  investigating  the  role  of  these
iRNAs  in  carcinogenesis  is  conﬂicting.  miR-23a  and  miR-
7a  was  shown  to  be  down  regulated  in  oral  SCC,22
hereas  recently  Peng  et  al.  showed  that  miR-23a  promotes
hemoresistance  to  cisplatin  chemotherapy  in  tongue  SCC.23
iR-23a  and  27-a  are  also  down  regulated  in  acute  promy-
locytic  leukemia  whereas  they  are  up  regulated  in  acute
yeloid  leukemia,  acute  lymphoblastic  leukemia,  gastric
ancer  and  hepatic  cancer.21 In  the  light  of  recent  litera-
ure  it  is  obvious  that  these  miRNAs  may  behave  different
n  pathogenesis  of  different  cancers,  they  may  act  as  tumor
uppressor  gene  in  one  cancer  while  oncogene  in  another.
n  our  study  miR-23a  and  27a  were  shown  to  be  down  reg-
lated  in  serum  samples  of  benign  salivary  gland  tumors.
iR-23a  was  also  down  regulated  in  malignant  tumor  group
ompared  to  control  group  in  serum  samples.  miR-23a  may
ehave  like  a  tumor  suppressor  gene  in  both  benign  and
alignant  salivary  gland  tumors.
When  tissue  and  plasma  samples  were  compared  among
enign  and  malignant  salivary  gland  tumors  in  our  study;
here  was  a  2.3656  fold  up-regulation  (p  =  0.01357)  of
iR-199a-5p  in  tissue  samples  and  3.5  fold  up  regulation
p  = 0.042)  in  serum  samples  of  malignant  tumors.  This
iRNA  was  also  shown  to  be  up-regulated  in  colon,  hepa-
ocellular,  gastric  cancer  and  malignant  melanoma.24,25 In
he  study  of  Liu  et  al.,26 miR-31  was  up-regulated  in  oral
CC  and  levels  were  decreased  after  treatment,  regarding
ossible  role  of  this  miRNA  as  a  marker  in  this  cancer.
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here  was  a  2244  fold  (p  =  0.0208)  up-regulation  of  this
iRNA  in  malignant  salivary  tumor  group  in  tissue  samples  in
ur  study.  miR-146b  was  shown  to  be  important  prognostic
actor  for  papillary  thyroid  cancer  patients,  more  expres-
ion  of  this  miRNA  in  tumor  cells  has  decreased  survival.27
iR-146b  expression  was  also  increased  in  anaplastic  thy-
oid  cancer  cells.28 However  for  breast  cancer,  expression
f  miR-146b  has  caused  reduction  in  metastatic  ability
y  suppressing  NF-kB  activity.29 In  our  study  there  was  a
.21  fold  up-regulation  (p  =  0.013)  of  miR-146b  in  malig-
ant  tumor  group  compared  to  benign  group  in  tumor
issue  specimens.  miR-345  was  found  to  have  a  prognostic
alue  in  prostate30 and  colorectal31 cancer.  In  our  study,
t  was  18  fold  up-regulated  (p  =  0.041)  in  malignant  group.
or  miR-30e;  it  was  shown  to  be  up-regulated  in  hepa-
ocellular  cancer32 whereas  down-regulated  in  anaplastic
hyroid  cancer.33 In  our  study  miR-30e  showed  15.06  fold
p-regulation  (p  = 0.034)  in  malignant  tumor  group’s  plasma
amples  compared  to  benign  group,  whereas  there  was  a
own-regulation  in  benign  tumor  group  compared  to  control
roup  (p  =  0.0007)  in  plasma  samples.
Studies  concerning  the  relationship  between  salivary
land  tumors  and  miRNAs  are  limited.  Mitani  et  al.  stud-
ed  miRNA  proﬁles  of  ACC  specimens  compared  to  normal
alivary  tissues.  They  found  that  over-expression  of  miR-17
nd  miR-20a  was  related  to  poor  outcome.34 He  et  al.  found
hat  expression  of  miR-181a  in  ACC  tumor  cells  decreased
etastatic  potential  of  the  tumor.4 Liu  et  al.  speculated
hat  suppression  of  miR-155  can  inhibit  cell  proliferation
nd  tumor  growth  for  ACC.35 Chen  et  al.  found  that  17
ifferent  miRNAs  had  statistically  signiﬁcant  fold  changes
n  the  metastatic  ACC  compared  to  non-metastatic  ones  in
ell  lines.5 Among  benign  salivary  gland  tumors  pleomorphic
denomas  were  investigated  for  possible  role  of  miRNAs  in
athogenesis.  Zhang  et  al.  found  that  17  different  miRNAs
ere  up-regulated  in  tumor  samples  including  miR-21.36 This
esult  was  not  consistent  with  our  study.  In  our  study;  there
as  a  down  regulation  of  miR-21  in  serum  samples  of  benign
umor  group  patients  compared  to  control  group.  This  dif-
erence  may  arise  from  two  points.  Firstly;  our  benign  tumor
roup  composed  of  multiple  pathologies,  not  only  pleomor-
hic  adenoma.  Secondly;  serum  samples  were  studied  in  the
ontrol  group  instead  of  tissue  samples.  In  another  study,
eit  et  al.  compared  the  miRNA  proﬁles  of  ACC  and  SCC  of
he  head  and  neck  region.  miR-214,  125a,  574,  199a/b-3p
nd  199a-5p  were  up-regulated  in  ACC  group.37 miR-199a
as  also  up-regulated  in  malignant  group  tissue  samples
n  our  study.  Recently  Kiss  et  al.38 demonstrated  possible
ole  of  down-regulation  of  miR-let-7b  and  miR-193b  in  sali-
ary  gland  ACC  pathogenesis.  Again  Kiss  et  al.39 found  seven
verexpressed  miRNAs  and  nine  down-expressed  miRNAs  in
alivary  ACC  tissue  samples  in  another  study.  Previously
ublished  studies  with  comparison  of  our  study  were  sum-
arized  in  Table  4.
In  our  study,  we  found  that  miR-21  and  miR-30e  were  up-
egulated  in  the  malignant  SGT  group  and  down  regulated
n  the  benign  group.  When  these  miRNAs  are  investigated
or  their  target  genes;  RPS7  and  LIMCH1  are  the  com-earched  using  Mirwalk  and  Mirtarbase  microRNA  database
ystems.)40,41 RPS7  gene  found  on  chromosome  2,  codes  a
ibosomal  protein  belonging  to  S7E  family,  and  LIMCH1  gene,
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Table  4  Previously  published  studies  concerning  the  relationship  between  MicroRNAs  and  salivary  gland  tumors.
Author  Published
year
Tumor  type  Study  design  Result
Zhang  et  al.36 2009  Pleomorphic
adenoma
Pleomorphic  adenoma  tissue  samples
were compared  with  normal  salivary
gland  tissue
Several  microRNAs  had  dysregulations
in  tumor  group.
Liu et  al.35 2012  ACC  ACC  tissue  samples  were  compared
with  pleomorphic  adenoma  and
normal  tissues  by  using  cell  culture.
miR-155  is  up  regulated  in  ACC  cells
and  causes  proliferation,  tumor
growth  and  increases  invasion
Mitani et  al.34 2013  ACC  Tumor  tissue  samples  were  compared
with  normal  salivary  gland  tissue
miR-17-92  cluster  expression  is
related  to  poor  outcome
He et  al.4 2013  ACC  Cell  culture  of  metastatic  cell  lines
were inoculated  to  mice
miR-181a  suppresses  metastasis  in
ACC
Chen et  al.5 2014  ACC  Cell  cultures  were  obtained  from
metastatic  and  non-metastatic  cell
lines  of  ACC
17  microRNAs  had  dysregulation  in
metastatic  cell  lines.
Veit et  al.37 2015  ACC  ACC  tissue  samples  were  compared
with  SCC  tissues.
miR-214,  125a,  574,  199a/b-3p,
199a-5p  were  up-regulated  in  ACC.
Kiss et  al.39 2015  ACC  ACC  tissue  samples  were  compared
with  normal  salivary  gland  tissue
7  microRNAs  were  upregulated  and  9
were downregulated.
Kiss et  al.38 2015  ACC  ACC  tissue  samples  were  compared
with  normal  salivary  gland  tissue
miR-let-7b  and  miR-193b  were  down
regulated  in  tissue  samples
Cinpolat et  al.a Benign  and
malignant
SGTs
(1)  Comparison  of  saliva  and  serum
samples  between  benign  tumors,
malign  tumors  and  control  group.
(2)  Comparison  of  tissue  samples
between  benign  and  malignant  SGT
group.
Dysregulation  in  expression  of
different  types  of  microRNAs  occur
according  to  biological  behavior  of
the  SGT.  Mir-21and  30e  are
down-regulated  in  benign  SGT  group,
up-regulated  in  malignant  ones.
icro
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RACC, adenoid cystic carcinoma; SGT, salivary gland tumors; miR, m
a Presented study.
found  on  chromosome  4,  codes  zinc  ion-binding  proteins.40,41
With  future  studies,  zinc  ion-binding  proteins  and  ribo-
somal  proteins  belonging  to  S7E  family  may  be  new  target
molecules  for  differing  biological  behavior  of  the  salivary
gland  tumors  in  serum  samples  and/or  ﬁne  needle  aspiration
biopsy  results.
Although  our  malignant  tumor  sample  size  seems  to  be
small,  there  have  been  published  articles  investigating  the
roles  of  miRNAs  in  SGT  carcinogenesis  with  similar  sample
size.  In  the  study  of  Veit  et  al.37 they  had  comparison  of  5
tumor  tissue  samples  of  ACC  with  10  tumor  tissue  samples
of  SCC.  In  the  study  of  Liu  et  al.35 they  compared  10  cases
of  ACC  with  4  cases  of  pleomorphic  adenoma  and  8  nor-
mal  parotid  gland  tissues.  Recently  Kiss  et  al.39 published
their  study  with  only  two  cases  of  salivary  ACCs.  We  think
that  our  results  are  meaningful  for  investigation  of  miRNA
pathogenesis  in  SGTs.
Conclusion
As  a  result;  under  the  light  of  previously  published  articles
and  current  study;  we  could  speculate  that  miRNAs  may  have
a  role  in  salivary  gland  tumor  pathogenesis.  Dysregulation
of  miRNA  type  differs  according  to  the  biological  behav-
ior.  miR-21  and  miR-30e  may  have  a  critical  role  in  salivary
gland  tumor  development  with  targeting  RPS7  and  LIMCH1
genes.RNA.
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